Physician profile
Peter P Ferrera
NPI 1366481384
$3,207.89
in general payments reported to CMS, 2019-2025
31 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $395 · 2021: $81.84 · 2022: $451 · 2023: $318 · 2024: $1,185 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $351.67 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $323.13 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Tela Bio, INC. | $299.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $254.21 | 2019-2023 | |
| Pfizer INC. | $243.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.95 | 2024-2025 | Jardiance |
| Teleflex LLC | $166.68 | 2024 | Urolift |
| Boston Scientific Corporation | $154.10 | 2024 | Watchman Flx |
| Lilly USA, LLC | $151.75 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $137.31 | 2022-2025 | |
| Exact Sciences Corporation | $119.77 | 2024-2025 | Cologuard Collection Kit |
| Lantheus Medical Imaging, INC. | $112.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $106.05 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $87.56 | 2019-2024 | Xarelto |
| Dexcom, INC. | $75.12 | 2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.53 | 2022-2023 | Eliquis |
| Sunovion Pharmaceuticals INC. | $40.26 | 2020 | |
| Abbott Laboratories | $38.45 | 2021-2022 | |
| Analog Devices INC. | $31.54 | 2024 | Sensinel Cpm Wearable |
| Amgen INC. | $27.35 | 2025 | Repatha |
| Eisai INC. | $27.25 | 2021 | |
| Gilead Sciences, INC. | $26.55 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.96 | 2022 | |
| Daiichi Sankyo INC. | $23.86 | 2021 | |
| Lucid Diagnostics INC. | $22.20 | 2023 | |
| Merck Sharp & Dohme LLC | $21.16 | 2025 | Gardasil 9, Capvaxive |
| Allergan, INC. | $20.17 | 2020 | |
| Amarin Pharma, INC. | $20.01 | 2019 | |
| Nevro Corp. | $18.79 | 2022 | |
| Sumitomo Pharma America, INC. | $18.78 | 2023 | Gemtesa |
| Viatris Specialty LLC | $18.12 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ferrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.